Pediatric therapeutics, exist

Both children and the elderly experience swallowing problems with oral formulations. A limited market already exists in pediatric therapeutics which addresses this problem. Although development of rectal formulations for the elderly has not been addressed extensively, with the expanding number of patients in this age group, the need for acceptable alternatives to oral dosing may increase efforts to develop rectal formulations. 

I) does not represent a meaningful therapeutic benefit over existing therapies for pediatric patients and (II) is not likely to be used in a substantial number of pediatric patients. 

Little experience exists to define a minimum toxic dose. Most of the reported cases have been in the pediatric population amounts ingested in overdoses substantially larger than adult therapeutic doses have not resulted in fatalities. Manifestations of toxicity may include hypertension and tachycardia followed by hypotension and bradycardia. Ataxia, drowsiness, lethargy, or coma may be noted. Pupils may be pinpoint and not reactive to light. Diarrhea may occur. Extrapyramidal symptoms and cardiac dysrhythmias have been documented. 

---